Literature DB >> 35260827

The association of serum magnesium and chronic kidney disease: a two-sample mendelian randomization study of European descent.

Chenyang Hou1, Yun Wang2, Xinxia Sui2, Wei Xin3, Qingzhi Hou4, Jihu Yi2, Huichen Yao5, Weihua Liu6, Zhiyuan Yu7, Lichuan Xia8, Qing Guo9.   

Abstract

BACKGROUND: Previous observational studies focused on the association of serum magnesium (SMg) and chronic kidney disease (CKD), but the conclusion was inconsistent. To investigate the causal relationship of SMg and CKD, we performed a two-sample mendelian randomization (TSMR) analysis using publicly datasets.
METHOD: In mendelian randomization (MR) analysis, we used single nucleotide polymorphisms (SNPs) which had genetic statistical significance with SMg but not associated with kidney function and confounding factors as instrumental variable (IV). To select SNPs, we used publicly database of Genome Wide Association Study (GWAS) and Chronic Kidney Disease Genetics (CKDGen) Confirms. We used inverse-variance weighted (IVW), weighted median, MR-Egger regression, weighted mode, and simple mode approaches in TSMR analysis.
RESULTS: We selected 4 SNPs (rs4072037, rs7965584, rs11144134 and rs448378) as IV. In IVW approach, the result of MR analysis for CKD was OR = 0.55, 95% CI: 0.06, 4.75, P = 0.58; for estimated glomerular filtration rate from creatinine (eGFR)crea was β = -0.06, 95% CI: -1.08, 0.07, P = 0.39; for estimated glomerular filtration rate from cystatin C (eGFR)cys was β = -0.03, 95% CI: -0.43, 0.36, P = 0.86, respectively per SD increase in SMg. When subgroup by diabetes mellitus (DM), the results for DM-eGFRcrea was β = -0.33, 95% CI: -0.85, 0.19, P = 0.21; and for non-DM-eGFRcrea was β = -0.03, 95% CI: -0.16, 0.11, P = 0.71. The results of other four MR approaches were consistent with IVW approach (all P > 0.05).
CONCLUSION: Our TSMR analysis showed that SMg had no causal effect on kidney function and progress CKD in European descent. As for the results about overall population, the verified study is needed in future study.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35260827     DOI: 10.1038/s41430-022-01106-5

Source DB:  PubMed          Journal:  Eur J Clin Nutr        ISSN: 0954-3007            Impact factor:   4.884


  31 in total

Review 1.  Dietary Magnesium and Chronic Disease.

Authors:  Forrest H Nielsen
Journal:  Adv Chronic Kidney Dis       Date:  2018-05       Impact factor: 3.620

Review 2.  Magnesium and Progression of Chronic Kidney Disease: Benefits Beyond Cardiovascular Protection?

Authors:  Yusuke Sakaguchi; Takayuki Hamano; Yoshitaka Isaka
Journal:  Adv Chronic Kidney Dis       Date:  2018-05       Impact factor: 3.620

3.  Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016.

Authors:  Yan Xie; Benjamin Bowe; Ali H Mokdad; Hong Xian; Yan Yan; Tingting Li; Geetha Maddukuri; Cheng-You Tsai; Tasheia Floyd; Ziyad Al-Aly
Journal:  Kidney Int       Date:  2018-08-03       Impact factor: 10.612

4.  Serum magnesium, mortality, and cardiovascular disease in chronic kidney disease and end-stage renal disease patients: a systematic review and meta-analysis.

Authors:  Jiachuan Xiong; Ting He; Min Wang; Ling Nie; Ying Zhang; Yiqin Wang; Yunjian Huang; Bing Feng; Jingbo Zhang; Jinghong Zhao
Journal:  J Nephrol       Date:  2019-03-19       Impact factor: 3.902

5.  Effect of Magnesium on Glomerular Filtration Rate and Recovery of Hypertension in Women with Severe Preeclampsia.

Authors:  Chatchai Kreepala; Wongsakorn Luangphiphat; Alfredo Villarroel; Maethaphan Kitporntheranunt; Krittanont Wattanavaekin; Teeraya Piyajarawong
Journal:  Nephron       Date:  2017-10-20       Impact factor: 2.847

Review 6.  Dyslipidemia in patients with chronic kidney disease.

Authors:  Matthew R Hager; Archana D Narla; Lisa R Tannock
Journal:  Rev Endocr Metab Disord       Date:  2017-03       Impact factor: 6.514

Review 7.  Mendelian Randomization.

Authors:  Connor A Emdin; Amit V Khera; Sekar Kathiresan
Journal:  JAMA       Date:  2017-11-21       Impact factor: 56.272

8.  Factors associated with magnesemia in patients with chronic kidney disease.

Authors:  Chien-Te Lee; Yueh-Ting Lee; Wei-Hung Kuo; Terry Ting-Yu Chiou; Long-Chih Li; Hwee-Yeong Ng; Chia-An Chou; Wen-Chin Lee
Journal:  Magnes Res       Date:  2017-05-01       Impact factor: 1.115

9.  Changes in Trace Elements During Early Stages of Chronic Kidney Disease in Type 2 Diabetic Patients.

Authors:  Ching-Chiang Lin; Ching-Tang Shih; Chien-Hung Lee; Yeou-Lih Huang
Journal:  Biol Trace Elem Res       Date:  2018-03-28       Impact factor: 3.738

10.  Causal Effects of Genetically Predicted Cardiovascular Risk Factors on Chronic Kidney Disease: A Two-Sample Mendelian Randomization Study.

Authors:  Hui-Min Liu; Qin Hu; Qiang Zhang; Guan-Yue Su; Hong-Mei Xiao; Bo-Yang Li; Wen-Di Shen; Xiang Qiu; Wan-Qiang Lv; Hong-Wen Deng
Journal:  Front Genet       Date:  2019-05-03       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.